This guideline includes recommendations for verification of commercial US Food and Drug Administration–cleared microbial identification and antimicrobial susceptibility testing systems by clinical laboratory professionals to fulfill regulatory or quality assurance requirements for the use of these systems for diagnostic testing. This reaffirmed document has been reviewed and confirmed as suitable to remain published without revision to content, as of January 2020. The document’s next scheduled review is generally five years after the reaffirmation date.

CLSI M52 : 1ED 2015